Drug Database
AM

amphotericin B (Ampholip)

✓ Approved

Bharat Serums and Vaccines Limited · Small Molecule · Small Molecule

What is amphotericin B?

amphotericin B is a small molecule developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAmpholip
CompanyBharat Serums and Vaccines Limited
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bharat Serums and Vaccines Limited

Therapeutic Indications

amphotericin B is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersEndocardial disease✓ Approved
Infections and infestationsCandida infection✓ Approved
Infections and infestationsAspergillus infection✓ Approved

Related Research Articles

PubMedExperimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation2026-10-16

Hepatitis B Virus Recurrence After Liver Transplant for Hepatitis B Virus-Related Liver Disease: A Retrospective Analysis of Hepatitis B Immunoglobulin Discontinuation.

Aktuna Hakan H, Daniş Nilay N, Döngelli Hüseyin H, Bacakoğlu Aylin A et al.

Hepatitis B virus recurrence after liver transplant remains a clinically relevant issue, but the optimal duration and safety of hepatitis B immunoglobulin therapy, particularly its discontinuation, remain unclear. Here, we evaluated the incidence and risk factors of posttransplant hepatitis B virus recurrence and assessed outcomes following elective discontinuation of hepatitis B immunoglobulin in a real-world cohort. We conducted a retrospective single-center cohort study of consecutive adult patients who underwent liver transplant for hepatitis B virus-related liver disease between 1997 and 2023. Hepatitis B virus recurrence was defined as the reappearance of hepatitis B surface antigen and/or detectable hepatitis B virus DNA. We used Cox proportional hazards models to identify factors associated with recurrence and overall survival. We conducted a predefined subgroup analysis to evaluate patients who underwent elective discontinuation of hepatitis B immunoglobulin during antiviral therapy. Among 254 liver transplant recipients, 39 (15.4% ) developed posttransplant hepatitis B virus recurrence. In multivariable analysis, pretransplant hepatitis B virus DNA levels >5 log10 copies/mL (hazard ratio 3.68; 95% CI, 1.82-7.46) and hepato-cellular carcinoma at transplant (hazard ratio 2.38; 95% CI, 1.22-4.65) were independently associated with recurrence, whereas hepatitis D virus coinfection was inversely associated (hazard ratio 0.18; 95% CI, 0.08-0.43). Elective hepatitis B immunoglobulin discontinuation was not associated with increased hepatitis B virus recurrence and was primarily performed in clinically selected low-risk patients. Posttransplant hepatitis B virus recurrence was associated with reduced overall survival. In this long-term, real-world cohort, posttransplant hepatitis B virus recurrence was mainly driven by the pretransplant viral burden and oncological factors. Elective hepatitis B immunoglobulin discontinuation in carefully selected patients was not associated with increased recurrence, likely reflecting the underlying risk stratification rather than a causal protective effect. These findings support the use of individualized risk-based hepatitis B immunoglobulin strategies after liver transplant.

PMID 42885707
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Novel Biochemical Findings from Bothrops marajoensis Venom.

Oliveira Isadora I, Ferreira Isabela I, Jacob Beatriz B, Ramos Emilly E et al.

Bothrops marajoensis is a Brazilian pit viper whose venom remains poorly characterized compared with those of other medically important Bothrops species. In the present study, we performed a comparative biochemical characterization of B. marajoensis venom with six additional Bothrops venoms (B. alternatus, B. atrox, B. jararaca, B. jararacussu, B. moojeni, and B. neuwiedi). Venoms were analyzed by reversed-phase chromatography, electrophoresis, immunorecognition by commercial bothropic antivenom, phosphodiesterase activity, and their effects on the viability of differentiated C2C12 myotubes. Chromatographic and electrophoretic analyses revealed a largely conserved overall venom composition among species, with qualitative differences, although quantitative differences in protein relative abundance were evident. Bothropic antivenom recognized all venoms, indicating broad antigenic cross-reactivity despite venom variation. B. marajoensis exhibited intermediate phosphodiesterase (PDE) activity relative to other species evaluated, confirming functional variability among Bothrops venoms. In the cell viability assay, B. marajoensis displayed comparatively low apparent cytotoxicity toward differentiated C2C12 myotubes, maintaining higher cell viability than highly myotoxic venoms such as those of B. jararacussu and B. moojeni. These findings expand the biochemical characterization of B. marajoensis venom and demonstrate that, although venoms share the conserved toxin repertoire typical for Bothrops genus, quantitative differences influence its biological activities, preserving broad recognition by bothropic antivenom.

PMID 42883771
Read full article →
PubMedAging cell2026-10-16

Senescent Fibroblasts Impair B Cell Proliferation via Cell-Cell Contact.

Vezyrgianni Kassandra K, MacLeod Elizabeth E, Nutley Abigail A, Zhu Yuchen Y et al.

Ageing profoundly impairs vaccine efficacy, leaving older individuals highly susceptible to infectious diseases despite vaccination. Although B cells retain the intrinsic capacity to generate germinal centre (GC) responses in older people, age-associated defects in T cells, dendritic cells and follicular dendritic cells (FDCs) limit the development of high-affinity, class-switched antibody responses. Here, we hypothesised that senescent fibroblasts disrupt B cell activation and expansion, thus contributing to the diminution of the humoral response in ageing. To test this hypothesis, we established an in vitro system in which human tonsil-derived YK6 fibroblasts expressing CD40L are co-cultured with PBMC-derived B cells. B cell activation, proliferation, and phenotype in response to low- and high-stimulation conditions was determined in co-culture with control or bleomycin-treated YK6 fibroblasts. Control YK6 fibroblasts promoted B-cell activation and proliferation in both 2D and 3D cultures, whereas bleomycin-treated fibroblasts robustly inhibited B-cell proliferation without impairing early activation. Conditioned media from bleomycin-treated fibroblasts partially reduced B cell proliferation, although to a lesser extent than direct co-culture, suggesting cell-cell contact was key to inhibiting B cell proliferation. Bleomycin-treated YK6 fibroblasts upregulated genes associated with impaired lymphocyte responses, such as PDCD1LG2, which may impact B cell activation. Indeed, B cells co-cultured with bleomycin-treated fibroblasts failed to fully initiate glycolysis and were essentially unable to synthesise new protein. Together, these findings suggest that senescence-like changes in fibroblasts could restrict B-cell proliferative capacity, which may contribute to impaired B cell responses in ageing.

PMID 42885644
Read full article →
PubMedFoods (Basel, Switzerland)2026-10-16

Construction and Performance Evaluation of a Bifidobacterium Delivery System Based on TBP-SA Pickering Emulsion Gels.

Xu Xia X, Yang Zhiqiang Z, Shen Xueli X, Cao Yanan Y et al.

An emulsion gel (EG-B) was fabricated through in situ calcium crosslinking of Pickering emulsions stabilized by tartary buckwheat protein-sodium alginate (TBP-SA) nanocomplexes for the encapsulation and delivery of Bifidobacterium longum. Control samples, including free bacteria (Free-B), Pickering emulsions (PE-B), and oil-free hydrogels (HG-B), were used to assess encapsulation efficiency, microstructure, rheological properties, thermal stability, dilution stability, gastrointestinal resistance, storage stability, and colonic adhesion of EG-B. The EG-B exhibited a dual structure comprising a compact Pickering interfacial membrane and a continuous calcium alginate gel network with solid-like rheology (G'>>G″) and viscosity of approximately 100 Pa·s, achieving 92.66% encapsulation efficiency. Viable counts exceeded 6 log CFU/g after pasteurization (72 °C, 15 s) and reached 6.12 log CFU/g post-simulated gastrointestinal digestion, significantly surpassing those of PE-B (5.12 log CFU/g) and HG-B (4.45 log CFU/g). Furthermore, EG-B displayed the highest viable retention during 14-day storage at 4 °C and 25 °C, along with a greater colonic adhesion efficiency (55.64%) compared to PE-B (47.09%) and HG-B (44.65%). The combination of interfacial stabilization and gel network formation provided by the TBP-SA complex presents a straightforward, food-grade strategy for probiotic delivery.

PMID 42883609
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Phenotypic Characteristics of B-Cell Subsets in Children with Allergic Diseases.

Lipińska-Opałka Agnieszka A, Tomaszewska Agata A, Leśnik Monika M, Zdanowski Robert R et al.

B-cell subpopulations are increasingly recognized as important modulators of immune responses, yet their role in pediatric allergic diseases remains incompletely understood. This study aimed to characterize the phenotype and frequency of peripheral B-cell subsets in children with allergic diseases and to assess their relationship with clinical and laboratory parameters. The study included 59 children with asthma, atopic dermatitis, or allergic rhinitis and 19 healthy controls. Multicolor flow cytometry was used to analyze B-cell subpopulations, including CD19+CD24hiCD38hi, CD19+CD25+, and IgD-CD27+ cells. The children with allergic diseases exhibited significantly reduced percentages of CD19+CD25+ B cells and switched-memory B cells compared with the controls. Negative correlations were observed between selected B-cell subsets and eosinophil counts, suggesting an association with type 2 inflammation. In asthma, higher proportions of transitional B cells were associated with better disease control, whereas no significant relationship was found between B-cell subsets and atopic dermatitis severity. In allergic rhinitis, the frequency of CD19+CD25+FoxP3+ B cells differed according to disease control, with lower frequencies observed in children with uncontrolled compared with partially controlled disease. These findings indicate that changes in B-cell populations may be involved in the pathogenesis of allergic diseases in children and their clinical expression.

PMID 42883848
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

CD180-Associated B-Cell Alterations in Type 1 Diabetes and the In Vitro Effects of Chlorogenic Acid: An Integrated Transcriptomic and Experimental Study.

Wang Zihang Z, Mijit Arzu A, Han Rong R, Li Mengjia M et al.

Type 1 diabetes mellitus (T1DM) is an autoimmune disease involving progressive loss of pancreatic β-cells. Although B cells have been implicated in T1DM progression, the molecular characteristics associated with disease-related B-cell states remain unclear. Here, we investigated B-cell-associated molecular alterations in T1DM and explored the potential immunomodulatory effects of a natural compound. Public T1DM transcriptomic datasets were analyzed using differential expression analysis, WGCNA, and machine-learning approaches. Single-cell RNA sequencing was used to characterize Cd180 expression across B-cell states. Molecular docking and molecular dynamics simulations were used to explore potential interactions between CD180 and candidate compounds, and an exploratory DARTS assay was performed to assess CGA-associated changes in CD180 proteolytic susceptibility. CD180 expression was examined in pancreatic tissues from vehicle- and MSA-2-treated NOD mice. The effects of chlorogenic acid (CGA) were evaluated in vitro by exposing B cells to CGA during inflammatory stimulation, followed by washing and co-culture with MIN6 cells in CGA-free medium. Integrated transcriptomic analysis identified four T1DM-associated genes (CD180, KCNJ2, STEAP4, and ZXDA), among which CD180 showed the strongest association with B-cell-related immune alterations. Single-cell analysis showed increased Cd180 expression in inflammatory B-cell states together with enrichment of antigen-presentation-related programs. An exploratory DARTS experiment with matched loading-control data suggested altered CD180 proteolytic susceptibility following CGA exposure, although independent reproducibility remains to be established. In vitro, CGA exposure during inflammatory stimulation was associated with reduced CD180 expression in B cells and improved MIN6 cell viability and insulin-secretory responses during subsequent co-culture in CGA-free medium. CD180 is associated with inflammatory B-cell alterations in T1DM and may represent a candidate molecular feature of B-cell dysregulation. CGA treatment was associated with changes in CD180 expression in activated B cells and improved β-cell functional outcomes in vitro. These findings support further investigation of the relationship between CGA and CD180; however, whether the effects of CGA are specifically mediated through CD180 requires further experimental validation.

PMID 42884178
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amphotericin B